{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:17:17Z","timestamp":1793312237424,"version":"4.5.0"},"reference-count":110,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36 million new cases and almost 700,000 deaths annually. Approximately 21% of patients with CRC have metastatic disease at diagnosis. The objective of this article is to review the literature on the efficacy and safety of oral drugs available for the treatment of metastatic colorectal cancer (mCRC). Several such drugs have been developed, and fluoropyrimidines are the backbone of chemotherapy in this indication. They exert their antitumour activity by disrupting the synthesis and function of DNA and RNA. Oral fluoropyrimidines include prodrugs capecitabine, tegafur, eniluracil\/5-fluorouracil, tegafur\/uracil, tegafur\/gimeracil\/oteracil and trifluridine\/tipiracil (FTD\/TPI). Oral drugs offer several advantages over injectable formulations, including convenience, flexibility, avoidance of injection-related adverse events (AEs) and, in some circumstances, lower costs. However, oral drugs may not be suitable for patients with gastrointestinal obstruction or malabsorption, they may result in reduced treatment adherence and should not be co-administered with drugs that interfere with absorption or hepatic metabolism. Oral fluoropyrimidines such as capecitabine, as monotherapy or in combination with oxaliplatin, irinotecan or bevacizumab, are as effective as intravenous 5-fluorouracil (5-FU) in first-line treatment of mCRC. Other oral fluoropyrimidines, such as FTD\/TPI, are effective in patients with mCRC who are refractory, intolerant or ineligible for 5-FU. In addition, oral fluoropyrimidines are used in adjuvant treatment of mCRC. Regorafenib is an oral multikinase inhibitor used in patients in whom several previous lines of therapy have failed. Frequent AEs associated with oral drugs used in the treatment of CRC include hand-foot syndrome and gastrointestinal and haematological toxicities.<\/jats:p>","DOI":"10.1177\/17588359211009001","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T02:18:09Z","timestamp":1619749089000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":56,"title":["Oral drugs in the treatment of metastatic colorectal cancer"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4373-9978","authenticated-orcid":false,"given":"Pilar","family":"Garc\u00eda-Alfonso","sequence":"first","affiliation":[{"name":"Oncolog\u00eda M\u00e9dica, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Calle Doctor Esquerdo 46, Madrid, 28009, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s Jes\u00fas","family":"Mu\u00f1oz Mart\u00edn","sequence":"additional","affiliation":[{"name":"Oncolog\u00eda M\u00e9dica, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ortega Mor\u00e1n","sequence":"additional","affiliation":[{"name":"Oncolog\u00eda M\u00e9dica, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Soto Alsar","sequence":"additional","affiliation":[{"name":"Oncolog\u00eda M\u00e9dica, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Torres P\u00e9rez-Solero","sequence":"additional","affiliation":[{"name":"Oncolog\u00eda M\u00e9dica, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Blanco Codesido","sequence":"additional","affiliation":[{"name":"Oncolog\u00eda M\u00e9dica, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Aitana","family":"Calvo Ferrandiz","sequence":"additional","affiliation":[{"name":"Oncolog\u00eda M\u00e9dica, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvina","family":"Grasso Cicala","sequence":"additional","affiliation":[{"name":"Medical Affairs Servier, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"bibr1-17588359211009001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"bibr2-17588359211009001","unstructured":"Noone A, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975\u20132015, based on November 2017 SEER data submission. https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html (2017, accessed 27 August 2018)."},{"key":"bibr3-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1242458"},{"key":"bibr4-17588359211009001","first-page":"105","volume":"7","author":"Marley AR","year":"2016","journal-title":"Int J Mol Epidemiol Genet"},{"key":"bibr5-17588359211009001","first-page":"33","volume":"7","author":"T\u00e1rraga L\u00f3pez PJ","year":"2014","journal-title":"Clin Med Insights Gastroenterol"},{"key":"bibr6-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X08093607"},{"key":"bibr7-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235"},{"key":"bibr8-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.110"},{"key":"bibr9-17588359211009001","first-page":"1696","volume":"5","author":"Twelves C","year":"1999","journal-title":"Clin Cancer Res"},{"key":"bibr10-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00371-9"},{"key":"bibr11-17588359211009001","first-page":"331","volume":"67","author":"Delaunoit T","year":"2004","journal-title":"Acta Gastroenterol Belg"},{"key":"bibr12-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2005.00531.x"},{"key":"bibr13-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1186649"},{"key":"bibr14-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1038\/179663a0"},{"key":"bibr15-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040958"},{"key":"bibr16-17588359211009001","unstructured":"US Food and Drug Administration (FDA). Stivarga. New drug application approval letter. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2012\/203085Orig1s000ltr.pdf (2012, accessed 18 October 2018)."},{"key":"bibr17-17588359211009001","unstructured":"European Medicines Agemcu. Stivarga. EPAR summary for the public. https:\/\/www.ema.europa.eu\/documents\/overview\/stivarga-epar-summary-public_en.pdf (2013, accessed 18 October 2018)."},{"key":"bibr18-17588359211009001","unstructured":"Taiho Oncology. Trifluridine and tipiracil (TAS-102). Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207981s000lbl.pdf (2015, accessed 20 February 2018)."},{"key":"bibr19-17588359211009001","unstructured":"Les Laboratoires Servier. TAS-102 (Lonsurf). Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003897\/WC500206246.pdf (2016, accessed 20 February 2018)."},{"key":"bibr20-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-4-288"},{"key":"bibr21-17588359211009001","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198916040-00002"},{"key":"bibr22-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074"},{"key":"bibr23-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2239"},{"key":"bibr24-17588359211009001","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2001.n.009"},{"key":"bibr25-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.01.005"},{"key":"bibr26-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00059-7"},{"key":"bibr27-17588359211009001","unstructured":"Roche Ltd. Capecitabine. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000316\/WC500058151.pdf (2006, accessed 20 February 2018)."},{"key":"bibr28-17588359211009001","unstructured":"Genetech USA Inc. Capecitabine. Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020896s037lbl.pdf (2015, accessed 20 February 2018)."},{"key":"bibr29-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2282"},{"key":"bibr30-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.21.4097"},{"key":"bibr31-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601676"},{"key":"bibr32-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1519"},{"key":"bibr33-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx122"},{"key":"bibr34-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70363-7"},{"key":"bibr35-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1783-3"},{"key":"bibr36-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"bibr37-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"bibr38-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70156-7"},{"key":"bibr39-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf089"},{"key":"bibr40-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.035"},{"key":"bibr41-17588359211009001","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.9.33"},{"key":"bibr42-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf108"},{"key":"bibr43-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-007-0250-9"},{"key":"bibr44-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.009"},{"key":"bibr45-17588359211009001","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2015.1104689"},{"key":"bibr46-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605261"},{"key":"bibr47-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2013.12.004"},{"key":"bibr48-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605663"},{"key":"bibr49-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283417f3e"},{"key":"bibr50-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70154-2"},{"key":"bibr51-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605907"},{"key":"bibr52-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1159\/000351240"},{"key":"bibr53-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1293-y"},{"key":"bibr54-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0406"},{"key":"bibr55-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60613-2"},{"key":"bibr56-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.384"},{"key":"bibr57-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006453500629"},{"key":"bibr58-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006401432488"},{"key":"bibr59-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.7.1635"},{"key":"bibr60-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0681-1"},{"key":"bibr61-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008379802642"},{"key":"bibr62-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1450"},{"key":"bibr63-17588359211009001","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2010.n.007"},{"key":"bibr64-17588359211009001","first-page":"4039","volume":"43","author":"El Sayed YM","year":"1983","journal-title":"Cancer Res"},{"key":"bibr65-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn067"},{"key":"bibr66-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197907)44:1<48::AID-CNCR2820440109>3.0.CO;2-C"},{"key":"bibr67-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.2.107"},{"key":"bibr68-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1159\/000055262"},{"key":"bibr69-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.123"},{"key":"bibr70-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.129"},{"key":"bibr71-17588359211009001","first-page":"385","volume":"19","author":"Bayoglu IV","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"key":"bibr72-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602913"},{"key":"bibr73-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1159\/000209334"},{"key":"bibr74-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1177\/1758834012441049"},{"key":"bibr75-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1101-6"},{"key":"bibr76-17588359211009001","unstructured":"Adis Insight. Drug profile. Tegafur\/uracil. https:\/\/adisinsight.springer.com\/drugs\/800008791 (2019, accessed 27 May 2020)."},{"key":"bibr77-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1007\/s11888-006-0032-9"},{"key":"bibr78-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.937706"},{"key":"bibr79-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70490-X"},{"key":"bibr80-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2014.06.004"},{"key":"bibr81-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70181-9"},{"key":"bibr82-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx816"},{"key":"bibr83-17588359211009001","unstructured":"Taiho Pharma. News release: phase III clinical trial results of TS-1 on metastatic colorectal cancer published in digital version of Lancet Oncology. https:\/\/www.taiho.co.jp\/en\/release\/2013\/20131111.html (2013, accessed 16 September 2019)."},{"key":"bibr84-17588359211009001","unstructured":"European Medicines Agency (EMA). Teysuno. EPAR summary for the public. https:\/\/www.ema.europa.eu\/documents\/overview\/teysuno-epar-summary-public_en.pdf (2011, accessed 23 October 2018)."},{"key":"bibr85-17588359211009001","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11050199"},{"key":"bibr86-17588359211009001","unstructured":"European Medicines Agency (EMA). EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/fluorouracil-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing_en.pdf (2020, accessed 28 May 2020)."},{"key":"bibr87-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(00)00253-7"},{"key":"bibr88-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00477.x"},{"key":"bibr89-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0633-9"},{"key":"bibr90-17588359211009001","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21873\/anticanres.11150","volume":"36","author":"Chen J","year":"2016","journal-title":"Anticancer Res"},{"key":"bibr91-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.06.001"},{"key":"bibr92-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70345-5"},{"key":"bibr93-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3245"},{"key":"bibr94-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy149.021"},{"key":"bibr95-17588359211009001","unstructured":"Institut de Recherches Internationales Servier. An open-label, randomised, phase III study cOmparing trifLuridine\/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study) [EU Clinical Trials Registry number: 2017-004059-22]. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004059-22\/GB (2017, accessed 21 February 2019)."},{"key":"bibr96-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30425-4"},{"key":"bibr97-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.637"},{"key":"bibr98-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.647"},{"key":"bibr99-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2017.01.003"},{"key":"bibr100-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0140-6"},{"key":"bibr101-17588359211009001","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Stivarga. Prescribing information. http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Stivarga_PI.pdf (2012, accessed 23 October 2018)."},{"key":"bibr102-17588359211009001","volume":"7","author":"Chionh F","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr103-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.06.027"},{"key":"bibr104-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.008"},{"key":"bibr105-17588359211009001","first-page":"192","volume":"81","author":"Wakisaka S","year":"1990","journal-title":"Fukuoka Igaku Zasshi"},{"key":"bibr106-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601137"},{"key":"bibr107-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0240"},{"key":"bibr108-17588359211009001","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.04.002"},{"key":"bibr109-17588359211009001","unstructured":"University of Southern California. A phase I\/II study of regorafenib and pembrolizumab in metastatic colorectal cancer patients in 3rd and 4th line setting [ClinicalTrial.gov number: NCT03657641]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03657641 (2018, accessed 26 June 2020)."},{"key":"bibr110-17588359211009001","unstructured":"City of Hope Medical Center. A phase I clinical trial of regorafenib, nivolumab, and ipilimumab in advanced chemotherapy resistant metastatic MSS colorectal cancer [ClinicalTrials.gov number: NCT04362839]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04362839 (2020, accessed 26 June 2020)."}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211009001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359211009001","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211009001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:25:46Z","timestamp":1777587946000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359211009001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":110,"alternative-id":["10.1177\/17588359211009001"],"URL":"https:\/\/doi.org\/10.1177\/17588359211009001","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"17588359211009001"}}